(0)
Capital will enable continued advancement of GenapSys electronic-based, next-generation sequencing platform
REDWOOD CITY, Calif., May 27, 2021 /PRNewswire/ GenapSys, Inc. (GenapSys), a company developing a highly accurate and scalable electronic sequencing platform, today announced it has raised $70 million in a Series D equity financing. Investors in the round included Farallon Capital Management, L.L.C., Soleus Capital, an affiliate of PBM Capital, and additional new investors. Proceeds from this financing will be used to continue advancing GenapSys semiconductor based next-generation sequencing (NGS) platform. We are delighted to partner with this world-class group of investors who together share our broad strategic vision of delivering an affordable, scalable genomic sequencing ecosystem that empowers both academic and clinical research, said Jason Myers, Ph.D., Chief Executive Officer of GenapSys. We look forward to leveraging our Board s strategic insight to acce
GenapSys Announces $70 Million in Series D Equity Financing and Expansion of its Board of Directors
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The Top 25 Healthcare Investors of 2021
Share Article NEW YORK (PRWEB) May 25, 2021 GrowthCap is pleased to announce The Top 25 Healthcare Investors of 2021. In our inaugural year for these awards, we wanted to bring forth and recognize not only the most experienced and talented investors in healthcare but also those that help advance innovation across the sector. Whether in healthcare software, healthcare services, medical technologies, biotechnology, the connected patient experience, or other areas, these accomplished individuals have demonstrated a deep commitment to healthcare and as a result have succeeded both from a business standpoint as well as in having significant societal impact.
Eptam Precision buys medical device maker
Print
Eptam Precision Solutions is continuing to grow by purchasing medical-component maker Mendell Machine and Manufacturing Inc. for undisclosed terms.
Mendell manufactures custom implantable plastic and metal medical devices, specializing in precision computer numerically controlled (CNC) micro-machining. The company serves the endovascular, structural heart and cardiovascular markets, providing micro-surgical components, micro-cutters and micro-housings. For the orthopedics OEM market, it offers implants, plates, cages, stems and screws.
Mendell s services include multiaxis Swiss turning, prototype machining, five-axis mill turning and in-house finishing operations. The company employs around 80 at its 52,000-square-foot facility in Lakeville, Minn.
Eptam, based in Northfield, N.H., employs more than 450 there and at operations in Colorado and New Jersey. In addition to serving the medical market, Eptam performs custom machining for
Share:
COPENHAGEN, Denmark, 18 May 2021 /PRNewswire/ Novo Holdings today announced that it has led the oversubscribed US$125 million Series C financing in Hummingbird Bioscience (Hummingbird), an innovative clinical-stage biotech company focused on developing precision therapies against difficult-to-drug targets to improve treatment outcomes. This is one of the first investments in a privately-held Asian biotech company by Novo Holdings. Novo Holdings recently established an Asian life sciences investment platform in Singapore, Novo Holdings Equity Asia Pte. Ltd. ( Novo Holdings Asia ). Kenneth Harrison, Partner, Novo Ventures, will join Hummingbird s board of directors.
Hummingbird, headquartered in Singapore and the US, is developing a broad pipeline of first- and best-in-class drug candidates across multiple indications for the treatment of cancer. Proceeds from the financing will be used to advance the clinical development of Hummingbird s lead assets including HMBD-001,
vimarsana © 2020. All Rights Reserved.